Aldeyra Therapeutics Inc (ALDX) Given Consensus Recommendation of “Buy” by Brokerages

Aldeyra Therapeutics Inc (NASDAQ:ALDX) has been assigned an average recommendation of “Buy” from the seven research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $17.42.

Several analysts have issued reports on ALDX shares. Zacks Investment Research raised Aldeyra Therapeutics from a “sell” rating to a “buy” rating and set a $6.75 price target on the stock in a research note on Tuesday, November 14th. ValuEngine downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. Canaccord Genuity reissued a “buy” rating and issued a $27.00 price target (up previously from $12.00) on shares of Aldeyra Therapeutics in a research note on Wednesday, September 13th. Cantor Fitzgerald initiated coverage on Aldeyra Therapeutics in a research report on Tuesday, October 24th. They issued an “overweight” rating and a $22.00 target price on the stock. Finally, Cowen reaffirmed an “outperform” rating and issued a $14.00 target price (up previously from $9.00) on shares of Aldeyra Therapeutics in a research report on Thursday, September 14th.

Shares of Aldeyra Therapeutics (NASDAQ:ALDX) opened at $6.55 on Tuesday. Aldeyra Therapeutics has a 12 month low of $3.80 and a 12 month high of $11.90. The stock has a market capitalization of $125.22, a PE ratio of -4.65 and a beta of 0.53. The company has a quick ratio of 20.35, a current ratio of 20.35 and a debt-to-equity ratio of 0.02.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.09. equities research analysts forecast that Aldeyra Therapeutics will post -1.39 earnings per share for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC increased its position in shares of Aldeyra Therapeutics by 6.9% in the third quarter. Perceptive Advisors LLC now owns 3,085,458 shares of the biotechnology company’s stock valued at $22,215,000 after acquiring an additional 200,000 shares during the last quarter. Sphera Funds Management LTD. increased its position in shares of Aldeyra Therapeutics by 19.2% in the third quarter. Sphera Funds Management LTD. now owns 1,044,131 shares of the biotechnology company’s stock valued at $7,518,000 after acquiring an additional 168,200 shares during the last quarter. 683 Capital Management LLC increased its position in shares of Aldeyra Therapeutics by 59.1% in the third quarter. 683 Capital Management LLC now owns 835,514 shares of the biotechnology company’s stock valued at $6,016,000 after acquiring an additional 310,421 shares during the last quarter. Virtu KCG Holdings LLC acquired a new stake in shares of Aldeyra Therapeutics in the second quarter valued at about $104,000. Finally, Vanguard Group Inc. increased its position in shares of Aldeyra Therapeutics by 3.2% in the second quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after acquiring an additional 9,407 shares during the last quarter. 47.89% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Aldeyra Therapeutics Inc (ALDX) Given Consensus Recommendation of “Buy” by Brokerages” was first published by BBNS and is owned by of BBNS. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://baseballnewssource.com/markets/aldeyra-therapeutics-inc-aldx-given-consensus-recommendation-of-buy-by-brokerages/1819590.html.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Analyst Recommendations for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.